GlassScriptPhysician profile
Gary S Toig
NPI 1881771798
$1,794.63
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $655 · 2021: $92.47.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $406.50 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $286.81 | 2019-2021 | |
| Novo Nordisk INC | $264.70 | 2019-2020 | |
| Assertio Therapeutics, INC. | $119.40 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.51 | 2019 | |
| Horizon Therapeutics Plc | $79.84 | 2020-2021 | |
| Gilead Sciences, INC. | $72.42 | 2019-2020 | |
| Optinose US, INC. | $64.78 | 2019 | |
| Abbvie INC. | $62.02 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $50.35 | 2019 | |
| Lilly USA, LLC | $49.34 | 2019-2020 | |
| Allergan, INC. | $47.63 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $37.43 | 2020 | |
| Ascend Therapeutics US, LLC | $36.05 | 2019 | |
| Pfizer INC. | $28.64 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Promius Pharma LLC | $23.73 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.19 | 2019 | |
| Bausch Health US, LLC | $15.20 | 2019 | |
| Glaxosmithkline, LLC. | $11.90 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.19 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Toig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.